This is not only the case for immune checkpoint inhibitors (ICIs), which directly derepress anti-tumor T cell immunity, but also for targeted BRAF and MEK inhibitors, the efficacy of which has been at least partly attributed to immune engagement23–28. This evidence concerns the gene MAP2K7 and neoplasm.